BIOMAT Database Logo BIOMAT Database Logo

Safety and efficacy of intensified versus standard dosing regimens of enteric-coated mycophenolate sodium in de novo renal transplant patients. 2011

Claudia Sommerer, and Petra Glander, and Wolfgang Arns, and Tofan Ariatabar, and Stefan Kramer, and Eva-Maria Vogel, and Maria Shipkova, and Wolfgang Fischer, and Lutz Liefeldt, and Ruth Hackenberg, and Jan Schmidt, and Martin Zeier, and Klemens Budde
Department of Nephrology, Heidelberg University Hospital, Heidelberg, Germany. claudia.sommerer@med.uni-heidelberg.de

BACKGROUND Efficacy and safety of an intensified dosing (ID) regimen of enteric-coated mycophenolate sodium (EC-MPS), which achieves higher mycophenolic acid exposure early posttransplantation, were evaluated in comparison with a standard dosing (SD) regimen. METHODS In total, 128 de novo kidney transplant recipients treated with basiliximab induction, cyclosporine A, and steroids were randomized (1:1) to receive EC-MPS as SD (1440 mg/day; n=65) or ID (days 0-14: 2880 mg/day; days 15-42: 2160 mg/day; followed by 1440 mg/day; n=63). Efficacy parameters, safety, and tolerability were assessed over a 6-month study period. The primary endpoint was mean time to first occurrence of treatment failure. RESULTS Mean time to treatment failure was 130 days (95% confidence interval [CI]: 81-n/a) in the ID group versus 114 days (95% CI: 15-155) in the SD group (P=0.36). Similar percentages (ID 30.2%; SD 36.9%) experienced treatment failure. Biopsy-proven acute rejection occurred in 2 (3.2%) ID versus 11 (16.9%) SD patients (P<0.001). Three (2.3%) deaths (2 SD, 1 ID) and five (3.9%) graft losses (3 SD, 2 ID) occurred. Renal function, incidence of infection, and hematologic disorders were comparable in both study cohorts. Gastrointestinal disorders occurred in 51 (81.0%) ID and 49 (75.4%) SD patients with overall similar tolerability as assessed by the Gastrointestinal Symptom Rating Scale. CONCLUSIONS In this exploratory study, the EC-MPS ID regimen reduced the incidence of rejection and showed a comparable safety and tolerability profile to SD. Further examination of this approach in a larger patient cohort is now warranted to confirm these findings.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009173 Mycophenolic Acid Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION. Cellcept,Mycophenolate Mofetil,Mycophenolate Mofetil Hydrochloride,Mycophenolate Sodium,Mycophenolic Acid Morpholinoethyl Ester,Myfortic,RS 61443,RS-61443,Sodium Mycophenolate,Mofetil Hydrochloride, Mycophenolate,Mofetil, Mycophenolate,Mycophenolate, Sodium,RS61443
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D005260 Female Females
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Claudia Sommerer, and Petra Glander, and Wolfgang Arns, and Tofan Ariatabar, and Stefan Kramer, and Eva-Maria Vogel, and Maria Shipkova, and Wolfgang Fischer, and Lutz Liefeldt, and Ruth Hackenberg, and Jan Schmidt, and Martin Zeier, and Klemens Budde
Efficacy and safety of enteric-coated mycophenolate sodium in de novo and maintenance renal transplant patients.
January 2008, Transplantation proceedings,
Claudia Sommerer, and Petra Glander, and Wolfgang Arns, and Tofan Ariatabar, and Stefan Kramer, and Eva-Maria Vogel, and Maria Shipkova, and Wolfgang Fischer, and Lutz Liefeldt, and Ruth Hackenberg, and Jan Schmidt, and Martin Zeier, and Klemens Budde
Enteric-coated mycophenolate sodium in de novo pediatric renal transplant patients.
February 2009, Pediatric nephrology (Berlin, Germany),
Claudia Sommerer, and Petra Glander, and Wolfgang Arns, and Tofan Ariatabar, and Stefan Kramer, and Eva-Maria Vogel, and Maria Shipkova, and Wolfgang Fischer, and Lutz Liefeldt, and Ruth Hackenberg, and Jan Schmidt, and Martin Zeier, and Klemens Budde
Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing.
October 2012, Transplantation reviews (Orlando, Fla.),
Claudia Sommerer, and Petra Glander, and Wolfgang Arns, and Tofan Ariatabar, and Stefan Kramer, and Eva-Maria Vogel, and Maria Shipkova, and Wolfgang Fischer, and Lutz Liefeldt, and Ruth Hackenberg, and Jan Schmidt, and Martin Zeier, and Klemens Budde
Improved rejection prophylaxis with an initially intensified dosing regimen of enteric-coated mycophenolate sodium in de novo renal transplant recipients.
August 2011, Transplantation,
Claudia Sommerer, and Petra Glander, and Wolfgang Arns, and Tofan Ariatabar, and Stefan Kramer, and Eva-Maria Vogel, and Maria Shipkova, and Wolfgang Fischer, and Lutz Liefeldt, and Ruth Hackenberg, and Jan Schmidt, and Martin Zeier, and Klemens Budde
Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients.
March 2004, Transplantation proceedings,
Claudia Sommerer, and Petra Glander, and Wolfgang Arns, and Tofan Ariatabar, and Stefan Kramer, and Eva-Maria Vogel, and Maria Shipkova, and Wolfgang Fischer, and Lutz Liefeldt, and Ruth Hackenberg, and Jan Schmidt, and Martin Zeier, and Klemens Budde
Efficacy and safety of enteric-coated mycophenolate sodium in patients with de novo and maintenance renal transplantation.
April 2014, International journal of clinical practice. Supplement,
Claudia Sommerer, and Petra Glander, and Wolfgang Arns, and Tofan Ariatabar, and Stefan Kramer, and Eva-Maria Vogel, and Maria Shipkova, and Wolfgang Fischer, and Lutz Liefeldt, and Ruth Hackenberg, and Jan Schmidt, and Martin Zeier, and Klemens Budde
Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients.
February 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
Claudia Sommerer, and Petra Glander, and Wolfgang Arns, and Tofan Ariatabar, and Stefan Kramer, and Eva-Maria Vogel, and Maria Shipkova, and Wolfgang Fischer, and Lutz Liefeldt, and Ruth Hackenberg, and Jan Schmidt, and Martin Zeier, and Klemens Budde
Evaluation of tolerability of enteric-coated mycophenolate sodium versus mycophenolate mofetil in de novo renal transplantation.
January 2015, Jornal brasileiro de nefrologia,
Claudia Sommerer, and Petra Glander, and Wolfgang Arns, and Tofan Ariatabar, and Stefan Kramer, and Eva-Maria Vogel, and Maria Shipkova, and Wolfgang Fischer, and Lutz Liefeldt, and Ruth Hackenberg, and Jan Schmidt, and Martin Zeier, and Klemens Budde
Enteric-coated mycophenolate sodium in de novo and maintenance kidney-pancreas transplant recipients.
January 2012, Clinical transplantation,
Claudia Sommerer, and Petra Glander, and Wolfgang Arns, and Tofan Ariatabar, and Stefan Kramer, and Eva-Maria Vogel, and Maria Shipkova, and Wolfgang Fischer, and Lutz Liefeldt, and Ruth Hackenberg, and Jan Schmidt, and Martin Zeier, and Klemens Budde
The efficacy and safety of intensified enteric-coated mycophenolate sodium with low exposure of calcineurin inhibitors in Chinese de novo kidney transplant recipients: a prospective study.
June 2016, International journal of clinical practice,
Copied contents to your clipboard!